Aclaris Therapeutics, Inc.
ACRSNASDAQHealthcare● Active
$4.36
+$0.00(+0.00%)
Market Cap$525794200
P/E Ratio—
52W High$5.15
52W Low$1.343
Aclaris Therapeutics, Inc. (ACRS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ACRS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.83M | $18.72M | $31.25M | $29.75M | $6.76M |
| Cost of Revenue | $2.09M | $2.79M | $18.08M | $11.96M | $4.71M |
| Gross Profit | $5.74M | $15.93M | $13.17M | $17.79M | $2.05M |
| Gross Margin %(computed) | 73.28% | 85.09% | 42.14% | 59.80% | 30.29% |
| Operating Expenses | |||||
| R&D Expenses | $52.65M | $33.59M | $98.38M | $77.81M | $43.81M |
| G&A Expenses | $21.97M | $22.20M | $31.10M | $25.13M | $23.62M |
| Total Operating Expenses | $82.11M | $157.86M | $110.53M | $107.65M | $91.77M |
| Operating Income | ($76.38M) | ($141.93M) | ($97.36M) | ($89.85M) | ($89.72M) |
| Operating Margin %(computed) | -975.91% | -758.18% | -311.55% | -302.01% | — |
| Interest Income | $7.64M | $7.95M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($64.92M) | ($132.06M) | ($88.85M) | ($86.91M) | ($90.86M) |
| Income Tax Expense | $0.00M | $0.00M | ($0.37M) | $0.00M | $0.00M |
| Net Income | ($64.92M) | ($132.06M) | ($88.48M) | ($86.91M) | ($90.86M) |
| Net Margin %(computed) | -829.58% | -705.48% | -283.15% | -292.11% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| Wtd Avg Shares | 122.66M | 77.30M | 69.81M | 65.21M | 56.73M |
| EBITDA | ($64.47M) | ($51.72M) | ($115.45M) | ($84.36M) | ($64.46M) |
| EBITDA Margin %(computed) | -823.78% | -276.28% | -369.46% | -283.53% | -953.42% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Aclaris Therapeutics, Inc. data
About Aclaris Therapeutics, Inc. (ACRS) Income Statement
Aclaris Therapeutics, Inc. (ACRS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ACRS reported revenue of $0.01B, gross profit of $0.01B (gross margin 73.28%), and net income of ($0.06B) — a net profit margin of -829.58%.
Frequently asked questions
ACRS · 4 questionsAclaris Therapeutics, Inc. (ACRS) reported revenue of $0.01B for 2025, down 58.2% year-over-year.
ACRS revenueACRS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09